A Phase 1B, Multicenter, Open-Label Study of the Safety and Efficacy of CHS-114 in Combination With Toripalimab With or Without Other Treatments in Participants With Advanced or Metastatic Solid Tumors (TREGCHECK 102)
This research study tests a new combination of medications, including an investigational drug called CHS-114 and an immunotherapy drug called toripalimab, to see how well they fight advanced cancer. The goal is to find safe and effective treatment options for patients whose cancer has spread and needs new approaches.
You might be eligible if you have specific types of advanced stomach or esophageal cancer that have grown after standard chemotherapy. Participants also need to have measurable tumors on scans and be generally recovered from previous cancer treatments.
Participants will receive study medications, which may include the new study drug, immunotherapy, and standard chemotherapy drugs. You will also need to provide tissue samples from your tumor and undergo regular health monitoring and scans.
This study is currently recruiting participants at multiple medical centers in the United States, including locations in Arizona, California, and Colorado.
- 1Tests a new drug combination against advanced or spreading solid tumors
- 2Currently active and recruiting patients at select medical centers
- 3Requires tumor tissue samples and regular monitoring during treatment
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.